• Explore /
  • Poster
  • / Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Abstract Video & Slides Poster

Authors

null

Navid Hafez

Yale University School of Medicine, New Haven, CT

Navid Hafez , Hatem Hussein Soliman , Siqing Fu , Karen A. Gelmon , Albiruni Ryan Abdul Razak , Pamela N. Munster , Ulka N. Vaishampayan , Shumei Kato , Primo Lara Jr., Elizabeth M. Swisher , Andrew B. Nixon , Abhijit Patel , Yu Shyr , S. Percy Ivy , Patricia LoRusso , Joseph W. Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02498613

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1077)

DOI

10.1200/JCO.2020.38.15_suppl.1077

Abstract #

1077

Poster Bd #

162

Abstract Disclosures

Similar Posters

First Author: Joseph W. Kim

First Author: Joseph W. Kim

First Author: James O'Bryan

First Author: Kamal Kant Kant Sahu